50 Jahre Aktiengesetz

On the 50th anniversary of the German Stock Corporation Act, which was originally ratified in 1965, leading legal scholars met at the birthplace of the law in Bonn to discuss current pressing challenges in this area of law. The results of the discussion, assembled in these conference proceedings, extend far beyond the confines of stock corporation law

High PM10 concentrations in the city of Buenos Aires and their relationship with meteorological conditions

In this work, the first long-term (eight years) record of hourly concentrations of carbon monoxide (CO), nitrogen dioxide (NO2) and particulate matter with diameter less than 10 μm (PM10) from three sites in the city of Buenos Aires is analysed. Considering the short-term guidelines suggested by the WHO, the daily mean PM10 concentrations present a relatively large number of exceedances at the three sites. Different statistical techniques are combined to study the relationship between these relatively high PM10 concentrations and relevant surface meteorological variables. For all pollutants and sites, wind speed shows the largest differences between the lowest and highest concentration quartiles. To further explore its role on daily mean PM10 concentration, a k-means algorithm is applied, grouping days with similar surface 1h-wind sequences. Five wind sequence clusters are found, presenting distinctive air quality data features. Two clusters (1 and 2) show that PM10 exceedances occurring with winds entering the city from the river represent between 10 and 21% of total events at the three sites. The frequency of exceedance under these conditions decreases with the distance to the coast. For cluster 1, the hourly PM10 concentration profile and its associated daily wind sequence suggest an important contribution to exceedance events from the city's southernmost power plant. Two clusters (3 and 4), exhibiting continental winds, account for 49–59% of the exceedances and co-occur with relatively drier air conditions. The correlation between CO and PM10 for days belonging to cluster 3 supports the hypothesis of a potential remote or distributed source contribution with SW winds. For cluster 4, differences among sites in the number of events under NNW winds suggest an important contribution from the city's widest avenue to the PM10 levels at the most coastal site. A large contribution coming from urban sources is also indicated for these winds. Finally, cluster 5, exhibiting low wind speed sequences, accounts for 23–33% of the exceedances at the three sites. The average PM10 concentration increases with persistence of this cluster, which could be a driver for exceedances. These results contribute to show the importance of simple methods such as clustering analysis to obtain insights into air quality features such as exceedances and their potential drivers. They also suggest that further efforts in monitoring, modelling and emission estimates may help to better understand local, urban and regional source contributions to these events in the city of Buenos Aires.Fil: Pineda Rojas, Andrea Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Centro de Investigaciones del Mar y la Atmósfera. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Centro de Investigaciones del Mar y la Atmósfera; ArgentinaFil: Borge, Rafael. Universidad Politécnica de Madrid; EspañaFil: Mazzeo, Nicolás A.. Universidad Tecnológica Nacional. Facultad Regional Avellaneda; ArgentinaFil: Saurral, Ramiro Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Centro de Investigaciones del Mar y la Atmósfera. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Centro de Investigaciones del Mar y la Atmósfera; ArgentinaFil: Matarazzo, Bruno Nicolas. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Ciencias de la Atmósfera y los Océanos; ArgentinaFil: Cordero, Jose M.. Universidad Politécnica de Madrid; EspañaFil: Kropff, Emilio. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentin

A process-based approach to predicting the effect of climate change on the distribution of an invasive allergenic plant in Europe

Ambrosia artemisiifolia is an invasive weed in Europe with highly allergenic pollen. Populations are currently well established and cause significant health problems in the French Rhône valley, Austria, Hungary and Croatia but transient or casual introduced populations are also found in more Northern and Eastern European countries. A process-based model of weed growth, competition and population dynamics was used to predict the future potential for range expansion of A.artemisiifolia under climate change scenarios. The model predicted a northward shift in the available climatic niche for populations to establish and persist, creating a risk of increased health problems in countries including the UK and Denmark. This was accompanied by an increase in relative pollen production at the northern edge of its range. The southern European limit for A.artemisiifolia was not expected to change; populations continued to be limited by drought stress in Spain and Southern Italy. The process-based approach to modelling the impact of climate change on plant populations has the advantage over correlative species distribution models of being able to capture interactions of climate, land use and plant competition at the local scale. However, for this potential to be fully realised, additional empirical data are required on competitive dynamics of A.artemisiifolia in different crops and ruderal plant communities and its capacity to adapt to local conditions

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.

none21noneEngelhardt M; Kleber M; Udi J; Wäsch R; Spencer A; Patriarca F; Knop S; Bruno B; Gramatzki M; Morabito F; Kropff M; Neri A; Sezer O; Hajek R; Bunjes D; Boccadoro M; Straka C; Cavo M; Polliack A; Einsele H; Palumbo A.Engelhardt M; Kleber M; Udi J; Wäsch R; Spencer A; Patriarca F; Knop S; Bruno B; Gramatzki M; Morabito F; Kropff M; Neri A; Sezer O; Hajek R; Bunjes D; Boccadoro M; Straka C; Cavo M; Polliack A; Einsele H; Palumbo A

Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.

Contains fulltext : 87573.pdf (publisher's version ) (Closed access)From 2002 to 2007, 49 myeloma patients who relapsed following autologous SCT were included in a prospective multicenter trial to determine the efficacy of a reduced melphalan/fludarabine regimen followed by allogeneic SCT from unrelated donors. All patients showed leucocyte and platelet engraftment after a median of 15 and 19 d, respectively. Grade II-IV acute graft-versus-host disease (GvHD) occurred in 25% of patients and 35% had chronic GvHD. Overall response rate at day 100 was 95% including 46% complete remission (CR). Cumulative incidence of non-relapse mortality at 1 year was 25% [95% confidence interval (CI): 13-37%] and was significantly lower for human leucocyte antigen (HLA)-matched compared to -mismatched SCT (10% vs. 53%, P = 0.001). The cumulative incidence of relapse at 3 years was 55% (95% CI: 40-70%). After a median follow up of 43 months, the estimated 5-year progression-free and overall survival rates were 20% and 26% respectively and were significantly better for matched in CR at day 100 (41% vs. 7%, P = 0.04 and 56% vs. 16%, P = 0.02). We conclude that optimal donor selection is mandatory for a low non-relapse mortality and high relapse incidence, which remains a major concern, should be improved by including post-transplant strategies to upgrade remission status

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma

Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. Conventional cytogenetics and fluorescence in situ hybridization are routinely assessed in MM, and when combined with ISS stage may attain an even better predictive potential. In order to achieve even more effective and individualized therapies, one crucial goal is the identification of genes and gene combinations that predict for response or resistance to chemotherapy. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in MM

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma

Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. Conventional cytogenetics and fluorescence in situ hybridization are routinely assessed in MM, and when combined with ISS stage may attain an even better predictive potential. In order to achieve even more effective and individualized therapies, one crucial goal is the identification of genes and gene combinations that predict for response or resistance to chemotherapy. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/ dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in M